Longidaza for injections 3000ME #5

Longidaza injections instruction

You can buy Longidaza injections here

Release form, composition and packaging

Lyophilisate for preparation of solution for injections in the form of a porous hygroscopic mass of white or white with a yellowish or brownish tinge.
 1 fl.
bovgialuronidazozoksimer (longidaza) 3000 IU
Excipients: mannitol - up to 20 mg.

pharmachologic effect

Bovgialuronidaza azoxymere is a conjugate of a proteolytic enzyme hyaluronidase with a high molecular weight carrier from the group of poly-1,4-ethylene piperazine N-oxide derivatives. Bovgialuronidazozoksimer possesses the entire spectrum of pharmacological properties inherent in medicines with hyaluronidase activity. The specific substrate of hyaluronidase are glycosaminoglycans (hyaluronic acid, chondroitin, chondroitin-4-sulfate, chondroitin-6-sulfate) - a "cementing" substance of connective tissue. Hydrolysis (depolymerization) decreases the viscosity of glycosaminoglycans, the ability to bind water and metal ions. As a result, the permeability of tissues increases, their trophicity improves, swelling decreases, hematomas dissolve, elasticity of cicatricially altered areas increases, contractures and adhesions are eliminated, and mobility of joints increases. The effect is most pronounced in the initial stages of the pathological process.
The clinical effect of bovgialuronidase azoxymere is significantly higher than the effect of native hyaluronidase. Conjugation increases the resistance of the enzyme to the action of temperature and inhibitors, increases its activity and leads to prolonged action. The enzymatic activity of bovgialuronidase azoxymere is maintained when heated to 37 ° C for 20 days, while native hyaluronidase under the same conditions loses its activity during the day. In bovgialuronidazozoxymere, the pharmacological properties of the carrier with chelating, antioxidant, anti-inflammatory and immunomodulatory activity are also preserved.
Bovgialuronidazozoksimer able to bind released during hydrolysis of glycosaminoglycans iron ions - activators of free-radical reactions, hyaluronidase inhibitors and stimulants of collagen synthesis, and thereby suppress the backlash, aimed at the synthesis of components of connective tissue. The polytropic properties of bovhialuronidase azoxymere are realized in a pronounced anti-fibrotic effect, experimentally proven by biochemical, histological and electron microscopic studies on a pneumofibrosis model.
Bovgialuronidaza azoxymere regulates (increases or decreases depending on the initial level) synthesis of inflammatory mediators (interleukin-1 and TNFα), can weaken the course of the acute phase of inflammation, increase the humoral immune response and resistance of the organism to infection. These properties allow the use of bovgialuronidazozoxymere during or after surgical treatment to prevent rough scarring and adhesions. The use of bovgialuronidazozoksimer in therapeutic doses during or after surgical treatment does not cause deterioration of the postoperative period or the progression of the infectious process; does not slow down bone repair.
Bovgialuronidazozoksimer with joint s / c or v / m administration increases the absorption of drugs, accelerates pain relief with the introduction of local anesthetics.
Bovgialuronidazozoksimer belongs to practically non-toxic compounds, does not violate the normal functioning of the immune system, does not affect the reproductive function of males and females of rats, pre-and postnatal development of offspring, does not have a mutagenic and carcinogenic effect. It has been experimentally proven that bovhialuronidase azoximer reduces the irritating and allergenic properties of the enzyme hyaluronidase. At therapeutic doses of bovgialuronidase, azoxymere is well tolerated by patients.

Pharmacokinetics

Suction and distribution

When parenteral administration of bovgialuronidase, the azoksimer is rapidly absorbed into the systemic circulation and reaches Cmax in the blood in 20-25 minutes. It is characterized by a high distribution rate, the half-distribution period is about 0.5 hours. It penetrates into all organs and tissues (including through the BBB and the hematophthalmic barrier).
The apparent Vd is 0.43 l / kg. Conjugation does not reduce the high bioavailability of the enzyme - bioavailability of at least 90%.

Metabolism and excretion

In the body, hyaluronidase undergoes hydrolysis, and the carrier is metabolized to low molecular weight compounds (oligomers), which are eliminated mainly through the kidneys in two phases. During the first day, 45-50% is excreted through the kidneys, no more than 3% through the intestines. Further, the rate of elimination slows down, by 4-5 days Longidaza injections are removed completely. T1 / 2 with i / m administration - 36 hours, with s / c administration - about 45 hours.

Indications

The drug is prescribed to adults as part of complex therapy for the treatment and prevention of diseases involving hyperplasia of the connective tissue.
In gynecology:
- treatment and prevention of adhesions in the pelvis with inflammatory diseases of the internal genital organs, including tubo-peritoneal infertility, intrauterine synechia, chronic endometritis.
In urology:
- treatment of chronic prostatitis;
- treatment of interstitial cystitis.
In surgery:
- treatment and prevention of adhesions after surgery on the abdominal organs;
- hypertrophic scars after injuries, burns, surgeries, pyoderma;
- nonhealing wounds.
In dermatology and cosmetology:
- treatment of limited scleroderma;
- treatment of keloid, hypertrophic, forming scars after pyoderma, injuries, burns, operations.
In pulmonology and phthisiology:
- treatment of pneumosclerosis, fibrosing alveolitis;
- treatment of tuberculosis (cavernous-fibrous, infiltrative, tuberculoma).
In orthopedics:
- treatment of joint contracture, arthrosis, ankylosing spondylitis, hematomas.
To increase bioavailability:
- with the joint introduction of antibacterial drugs in urology, gynecology, surgery, dermatology, pulmonology, to enhance the action of local anesthetics.

Contraindications for Longidaza injections

- acute infectious diseases;
- pulmonary hemorrhage and hemoptysis;
- fresh vitreous hemorrhage;
- Malignant neoplasms;
- acute renal failure;
- age up to 18 years (the results of clinical studies are absent);
- Hypersensitivity to drugs based on hyaluronidase.
With caution, Longidaza injections are prescribed for chronic renal failure (used no more than 1 time per week).

Dosage of Longidaza for injections

Longidaza injections are applied sc (to the site of the lesion or under scar-modified tissue) or intramuscularly at a dose of 3000 IU in a course of 5 to 25 injections (depending on the disease) with an interval between injections from 3 to 10 days.
Methods of use are chosen by the doctor depending on the diagnosis, the severity of the disease, the clinical course, the age of the patient. If necessary, a second course is recommended in 2-3 months.
In the case of treatment of diseases involving severe chronic productive process in the connective tissue, after the standard course, long-term maintenance therapy with Longidaza 3000 IU is recommended, with intervals between injections of 10-14 days.
To increase the bioavailability of medicinal and diagnostic agents, a dose of 1500 IU is recommended, with a preliminary dose of 10-15 min / ml or subcutaneous injection in the same place as the main drug.

Breeding

1. The contents of the ampoule or vial of the drug Longidaza 3000 IU dissolved in 1-2 ml of procaine solution (0.25% or 0.5%). In case of intolerance to procaine, Longidaza injections are dissolved in the same volume of a 0.9% solution of sodium chloride for injection or water for injection.
2. When used to increase the bioavailability, the contents of the ampoule or vial of the drug Longidaza 3000 ME are dissolved in 2 ml, and with a dose of 1500 ME in 1 ml of 0.9% sodium chloride solution for injection.
The solvent in the vial or ampoule must be introduced slowly, stand for 2-3 minutes, gently mix, not shaking, so as not to foam the protein. The prepared solution for parenteral administration is not subject to storage. Do not enter in / in!

Recommended schemes for prevention and treatment

For the prevention of adhesive disease and severe scarring after surgery on the abdominal organs and small pelvis v / m at a dose of 3000 ME 1 time in 3 days with a course of 5 injections. If necessary, the use of Longidaza injections can be continued by the general course up to 10 injections with the introduction of 1 time in 5 days.

For treatment

in gynecology:
- adhesions in the pelvis with inflammatory diseases of the internal genital organs - intramuscularly with 3000 IU once every 3-5 days with a course of 10-15 injections;
- tubal-peritoneal infertility - intramuscularly by 3000 ME in a general course of up to 15 injections: the first 5 injections 1 time in 3 days, then 1 time in 5 days.
in urology:
- chronic prostatitis - intramuscularly by 3000 ME 1 time in 5 days, a course of 10-15 injections;
- interstitial cystitis - in / m 3000 ME 1 every 5 days, a course of up to 10 injections.
in surgery:
- adhesive disease after surgery on the abdominal organs - in / m at a dose of 3000 ME 1 every 3-5 days in a course of 10 to 15 injections;
- nonhealing wounds - in / m in a dose of 3000 IU 1 time in 5 days in a course of 5-10 injections.
in dermatovenerology, cosmetology:
- limited scleroderma - in / m on 3000-4500 ME 1 every 3-5 days with a course of up to 20 injections. The dose and course are selected individually depending on the clinical course, stage, localization of the disease and the individual characteristics of the patient;
- keloid, hypertrophic and forming scars after pyoderma, burns, surgeries, injuries - intracipital or subcutaneous injection of the injection near the site of the lesion once every 3 days, with a course of up to 15 injections in the dosage of 3000-4500 ME. The dilution amount of the drug Longidaza is chosen by the doctor depending on the number of points of injection. If necessary, the course can be continued according to the scheme 1 time in 5 days up to 25 injections. Depending on the area of ​​skin lesion, the duration of scar formation, alternation of sc and or intramuscular administration is possible 1 time in 5 days at a dose of 3000 IU, with a course of up to 20 injections.
in pulmonology and phthisiology:
- pneumosclerosis - intramuscular by 3000 ME 1 time in 5 days with a course of 10 injections;
- fibrosing alveolitis - in / m at a dose of 3000 ME 1 time in 5 days with a course of 15 injections, then - supportive therapy 1 time in 10 days with a general course of up to 25 injections;
- tuberculosis - in / m in a dose of 3000 ME 1 time in 5 days with a course of up to 25 injections; depending on the clinical picture and the severity of the course of the disease, long-term therapy is possible (from 6 months to 1 year at a dose of 3000 IU once every 10 days).
in orthopedics:
- joint contractures - s / c near the site of injury at a dose of 3000 ME 1 time in 3 days with a course of 5 to 15 injections;
- arthrosis, ankylosing spondyloarthritis - s / c close to the lesion site in a dose of 3000 ME 1 time in 3 days with a course of up to 15 injections, if necessary, treatment can be continued with injections 1 time in 5 days. The duration of maintenance therapy is chosen by the doctor depending on the severity of the disease;
- hematomas - s / c near the site of injury at a dose of 3000 ME 1 time in 3 days with a course of up to 5 injections.
To increase bioavailability: with a joint sc or intramuscular injection with diagnostic or medicinal drugs (antibiotics, chemotherapy drugs, anesthetics, etc.) Longidaza injections are administered in 10-15 minutes in a dose of 1500 IU in the same way and in the same place as and the main drug.

Side effects

Often (> 1/100, <1/10) - pain at the injection site.
Sometimes (> 1/1000, <1/100), reactions can occur at the injection site in the form of skin redness, itching and swelling. All local reactions pass through 48-72 h.
Very rarely (<1/10 000) - allergic reactions.

Overdose

Overdose symptoms can manifest as chills, fever, dizziness, hypotension.
Treatment: the administration of Longidaza injections are stopped and symptomatic therapy is prescribed.

Drug interaction

Bovgialuronidazo azoksimer can be combined with antibiotics, antiviral, antifungal drugs, bronchodilators.
When used in combination with other drugs (antibiotics, local anesthetics, diuretics) bovgialuronidazozoksimer increases bioavailability and enhances their action.
When used together with large doses of salicylates, cortisone, ACTH, estrogen or antihistamine drugs, the enzymatic activity of bovgialuronidase azoxyimer can be reduced.
Do not use bovgialuronidazozoksimer simultaneously with drugs containing furosemide, benzodiazepines, phenytoin.

special instructions

If you need to stop taking the drug Longidaza injections, the cancellation can be carried out immediately, without gradually reducing the dose.
In case of skipping the introduction of a regular dose of Longidaza injections, its subsequent use should be carried out as usual, as indicated in this instruction or recommended by a doctor. The patient should not administer a double dose in order to compensate for missed doses.
Before starting treatment, the patient must inform the doctor about all medications taken.
With the development of an allergic reaction, the patient should stop using the drug Longidaza injections and consult a doctor.
In chronic renal failure, Longidaza injections are prescribed no more than 1 time per week.
Do not use the drug in the presence of visual signs of its unsuitability (packaging defect, change in the color of the powder).
Do not enter the drug Longidaza in the zone of acute infectious inflammation because of the danger of the spread of localized infection.

Influence on ability to drive motor transport and control mechanisms

The use of the drug Longidaza does not affect the ability to perform potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions (including driving, working with moving mechanisms).

Pregnancy and lactation

The use of the drug Longidaza for pregnant women and women during breastfeeding is contraindicated.

Use in childhood

The drug is contraindicated in children and adolescents under the age of 18 years.

In case of impaired renal function

Use of the drug in acute renal failure is contraindicated.
In chronic renal failure, the drug is prescribed no more than 1 time per week.

Pharmacy sales terms

You don't need a prescription to buy Longidaza injections.

Terms and conditions of storage

The drug should be stored in a dry, protected from light, out of reach of children at a temperature not higher than 15 ° C. Shelf life - 2 years. Do not apply after the expiration date.